Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOHAMMAD R BOLOURI

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1659322691
CMS profile
29086
Location
CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$8,393.72

33 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Lilly USA, LLC $6,389.29 14
Eisai Inc. $1,879.70 13
Otsuka America Pharmaceutical, Inc. $91.32 4
Lundbeck LLC $33.41 2

Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOHAMMAD R BOLOURI

NPI 1659322691 · CMS profile ID 29086

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CHARLOTTE, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1659322691?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1659322691?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1659322691?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
MOHAMMAD R BOLOURI, NPI 1659322691, CMS profile ID 29086, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–33 of 33 matching records. This page contains 33 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1659322691?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

33 matching records · $8,393.72 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 33 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–33 of 33.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Eisai Inc. $124.9912/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500638 CMS
Eisai Inc. $20.6512/02/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500640 CMS
Lundbeck LLC $18.2111/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251776384 CMS
Lilly USA, LLC $1,600.0011/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186768950 CMS
Lilly USA, LLC $600.0011/18/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186781585 CMS
Otsuka America Pharmaceutical, Inc. $23.0611/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227297476 CMS
Eisai Inc. $27.8211/12/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500634 CMS
Otsuka America Pharmaceutical, Inc. $23.0610/28/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227297474 CMS
Lilly USA, LLC $15.0810/19/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186818994 CMS
Lilly USA, LLC $16.8809/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186804093 CMS
Eisai Inc. $26.0709/22/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500632 CMS
Otsuka America Pharmaceutical, Inc. $18.0709/16/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227297472 CMS
Lilly USA, LLC $35.0009/11/2025 Travel and Lodging No dispute reported Delay: No
Change: NEW
06/30/2026 1186804095 CMS
Otsuka America Pharmaceutical, Inc. $27.1309/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1227297470 CMS
Lilly USA, LLC $4,000.0008/28/2025 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: NEW
06/30/2026 1186781591 CMS
Eisai Inc. $26.4608/14/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500630 CMS
Lilly USA, LLC $14.4208/11/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186757735 CMS
Lilly USA, LLC $15.0807/21/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186781589 CMS
Eisai Inc. $25.2406/26/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500628 CMS
Lilly USA, LLC $15.8006/23/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186768952 CMS
Eisai Inc. $22.5706/10/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500626 CMS
Lilly USA, LLC $15.0705/29/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186781587 CMS
Eisai Inc. $1,462.5005/23/2025 Compensation for serving as faculty or as a speaker for a medical education program No dispute reported Delay: No
Change: NEW
06/30/2026 1244500636 CMS
Eisai Inc. $25.9405/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500624 CMS
Lilly USA, LLC $15.8005/01/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186842573 CMS
Lilly USA, LLC $15.7003/31/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186804091 CMS
Eisai Inc. $33.9403/24/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500622 CMS
Lundbeck LLC $15.2003/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1251776380 CMS
Eisai Inc. $23.8603/05/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500620 CMS
Lilly USA, LLC $15.5102/18/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186796675 CMS
Eisai Inc. $29.1002/13/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500618 CMS
Eisai Inc. $30.5601/15/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1244500616 CMS
Lilly USA, LLC $14.9501/09/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1186818992 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,343.30 32
PY2020 $733.57 2
PY2021 $39.36 2
PY2022 $3,758.34 15
PY2023 $10,255.80 39
PY2024 $25,153.09 51
PY2025 $8,393.72 33

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,948,171.02 223
PY2024 Recipient $42,149.90 1
PY2024 Principal investigator $2,006,224.93 95
PY2023 Recipient $150.00 1
PY2023 Principal investigator $3,166,315.18 100
PY2022 Recipient $250.00 1
PY2022 Principal investigator $2,451,442.73 165
PY2021 Principal investigator $2,459,911.12 123
PY2020 Recipient $1,077.94 1
PY2020 Principal investigator $1,535,993.16 168
PY2019 Principal investigator $1,981,815.06 222

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

222 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Eisai Inc. $1,186.00 12/31/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522229
Principal investigator 1 Eisai Inc. $30,957.30 12/21/2019 Non-covered Recipient Entity
ANI Neurology, PLLC dba Alzheimer's Memory Center
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 705570565
Principal investigator 1 Eisai Inc. $150.00 12/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702522231
Principal investigator 1 Eisai Inc. $1,480.00 12/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702522233
Principal investigator 1 Eisai Inc. $2,904.00 12/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522235
Principal investigator 1 Eisai Inc. $1,387.00 12/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522237
Principal investigator 1 Eisai Inc. $2,967.00 12/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522239
Principal investigator 1 Eisai Inc. $2,904.00 12/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522241
Principal investigator 1 Eisai Inc. $1,387.00 12/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522243
Principal investigator 1 Eisai Inc. $1,387.00 12/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522245
Principal investigator 1 Eisai Inc. $2,967.00 12/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522247
Principal investigator 1 Eisai Inc. $2,904.00 12/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522249
Principal investigator 1 Eisai Inc. $1,387.00 12/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522251
Principal investigator 1 Eisai Inc. $1,387.00 12/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522253
Principal investigator 1 Eisai Inc. $1,442.00 12/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522255
Principal investigator 1 Eisai Inc. $2,904.00 12/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522257
Principal investigator 1 Eisai Inc. $1,387.00 12/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522259
Principal investigator 1 Genentech, Inc. $94,072.00 12/05/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 681105631
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 12/01/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703577825
Principal investigator 1 Eisai Inc. $2,496.00 11/26/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522271
Principal investigator 1 Eisai Inc. $4,165.00 11/26/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522273
Principal investigator 1 Eisai Inc. $2,360.00 11/26/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522275
Principal investigator 1 Eisai Inc. $2,496.00 11/26/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522277
Principal investigator 1 Eisai Inc. $1,186.00 11/26/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522279
Principal investigator 1 Eisai Inc. $2,360.00 11/26/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522281
Principal investigator 1 Eisai Inc. $2,496.00 11/26/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522285
Principal investigator 1 Eisai Inc. $2,496.00 11/26/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522287
Principal investigator 1 Genentech, Inc. $7,650.00 11/26/2019 Non-covered Recipient Entity
ANI NEUROLOGY PLLC
SC PROOF OF EFFICACY STUDY No dispute reported 06/30/2026 681118029
Principal investigator 1 Eisai Inc. $5,284.50 11/21/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522283
Principal investigator 1 Eisai Inc. $44,179.40 11/21/2019 Non-covered Recipient Entity
ANI Neurology, PLLC dba Alzheimer's Memory Center
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 705570557
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 11/01/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703577571
Principal investigator 1 Eisai Inc. $4,165.00 10/31/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522261
Principal investigator 1 Eisai Inc. $2,360.00 10/31/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522263
Principal investigator 1 Eisai Inc. $4,165.00 10/31/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522265
Principal investigator 1 Eisai Inc. $4,165.00 10/31/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522267
Principal investigator 1 Eisai Inc. $2,360.00 10/31/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522269
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $169.44 10/28/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703577689
Principal investigator 1 Avanir Pharmaceuticals, Inc. $202.40 10/23/2019 Non-covered Recipient Entity
ANI NEUROLOGY PLLC
15-AVP-786-302 No dispute reported 06/30/2026 656017081
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522031
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522033
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522035
Principal investigator 1 Eisai Inc. $1,576.00 10/15/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522037
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522039
Principal investigator 1 Eisai Inc. $1,387.00 10/15/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522041
Principal investigator 1 Eisai Inc. $1,576.00 10/15/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522043
Principal investigator 1 Genentech, Inc. $15,756.00 10/09/2019 Non-covered Recipient Entity
ANI NEUROLOGY PLLC
SC PROOF OF EFFICACY STUDY No dispute reported 06/30/2026 681074177
Principal investigator 1 Genentech, Inc. $2,250.00 10/09/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
PRODROMAL TO MILD AD No dispute reported 06/30/2026 681076047
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 10/01/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703577635
Principal investigator 1 Eisai Inc. $2,981.00 10/01/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522019
Principal investigator 1 Eisai Inc. $1,186.00 10/01/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522021
Principal investigator 1 Eisai Inc. $2,005.00 10/01/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522023
Principal investigator 1 Eisai Inc. $2,005.00 10/01/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522025
Principal investigator 1 Eisai Inc. $3,956.00 10/01/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522027
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $137.44 09/24/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703577325
Principal investigator 1 Eisai Inc. $192.60 09/19/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522029
Principal investigator 1 Eisai Inc. $1,388.00 09/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702522055
Principal investigator 1 Genentech, Inc. $103,364.00 09/08/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 681109211
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 09/01/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703577491
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $422.26 08/27/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703577323
Principal investigator 1 Eisai Inc. $4,651.00 08/23/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 702522227
Principal investigator 1 Avanir Pharmaceuticals, Inc. $5,780.85 08/22/2019 Non-covered Recipient Entity
ANI NEUROLOGY PLLC
15-AVP-786-302 No dispute reported 06/30/2026 656017079
Principal investigator 1 Eisai Inc. $1,836.00 08/20/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522127
Principal investigator 1 Eisai Inc. $2,904.00 08/20/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522129
Principal investigator 1 Eisai Inc. $1,387.00 08/20/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522131
Principal investigator 1 Eisai Inc. $1,387.00 08/20/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522133
Principal investigator 1 Eisai Inc. $1,387.00 08/20/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522135
Principal investigator 1 Eisai Inc. $1,836.00 08/20/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522137
Principal investigator 1 Eisai Inc. $2,904.00 08/20/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522139
Principal investigator 1 Eisai Inc. $1,387.00 08/20/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522141
Principal investigator 1 Eisai Inc. $4,178.00 08/15/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522045
Principal investigator 1 Eisai Inc. $2,360.00 08/15/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522047
Principal investigator 1 Eisai Inc. $4,165.00 08/15/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522049
Principal investigator 1 Eisai Inc. $2,360.00 08/15/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522051
Principal investigator 1 Eisai Inc. $2,496.00 08/15/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522053
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $2,000.00 08/13/2019 Non-covered Recipient Entity
NeuroTrials Research Inc
PoCC dose finding in Mild to Moderate AD No dispute reported 06/30/2026 708440329
Principal investigator 1 Eisai Inc. $1,234.00 08/13/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702522143
Principal investigator 1 Eisai Inc. $1,833.00 08/13/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702522145
Principal investigator 1 Eisai Inc. $200.00 08/06/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522125
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 08/01/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703577427
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $59.94 07/25/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703577321
Principal investigator 1 Genentech, Inc. $13,160.00 07/24/2019 Non-covered Recipient Entity
ANI NEUROLOGY PLLC
SC PROOF OF EFFICACY STUDY No dispute reported 06/30/2026 681097689
Principal investigator 1 Eisai Inc. $2,676.60 07/19/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 702522225
Principal investigator 1 Genentech, Inc. $66,296.00 07/10/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 681100385
Principal investigator 1 Eisai Inc. $956.00 07/09/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522057
Principal investigator 1 Eisai Inc. $75.00 07/09/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522059
Principal investigator 1 Eisai Inc. $2,005.00 07/09/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522061
Principal investigator 1 Eisai Inc. $3,956.00 07/09/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522063
Principal investigator 1 ACADIA Pharmaceuticals Inc $2,228.33 07/05/2019 Non-covered Recipient Entity
ANI NEUROLOGY PLLC
ACP-103-033 No dispute reported 06/30/2026 699989531
Principal investigator 1 Eisai Inc. $1,498.00 07/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522147
Principal investigator 1 Eisai Inc. $1,387.00 07/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522149
Principal investigator 1 Eisai Inc. $1,387.00 07/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522151
Principal investigator 1 Eisai Inc. $1,576.00 07/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522155
Principal investigator 1 Eisai Inc. $1,498.00 07/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522157
Principal investigator 1 Eisai Inc. $1,387.00 07/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522159
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 07/01/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703577167
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $239.76 06/25/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576735
Principal investigator 1 Eisai Inc. $2,800.00 06/25/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522153
Principal investigator 1 Eisai Inc. $2,800.00 06/25/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522161
Principal investigator 1 Eisai Inc. $1,387.00 06/25/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522163
Principal investigator 1 Eisai Inc. $2,904.00 06/25/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522165
Principal investigator 1 Eisai Inc. $1,537.00 06/25/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522167
Principal investigator 1 Eisai Inc. $1,632.00 06/25/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522169
Principal investigator 1 Eisai Inc. $1,387.00 06/25/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522171
Principal investigator 1 Eisai Inc. $1,576.00 06/25/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522173
Principal investigator 1 Eisai Inc. $2,904.00 06/25/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522175
Principal investigator 1 Eisai Inc. $1,537.00 06/25/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522177
Principal investigator 1 Eisai Inc. $1,632.00 06/25/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study With an Open-Label Extension Phase to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522179
Principal investigator 1 Avanir Pharmaceuticals, Inc. $10,561.62 06/20/2019 Non-covered Recipient Entity
ANI NEUROLOGY PLLC
15-AVP-786-302 No dispute reported 06/30/2026 656017077
Principal investigator 1 Eisai Inc. $180.00 06/06/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702522065
Principal investigator 1 Eisai Inc. $500.00 06/06/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702522067
Principal investigator 1 Eisai Inc. $280.00 06/06/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702522069
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 06/01/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576795
Principal investigator 1 Eisai Inc. $3,956.00 05/30/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522071
Principal investigator 1 Eisai Inc. $2,731.00 05/30/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522073
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $209.40 05/28/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576733
Principal investigator 1 Eisai Inc. $529.20 05/16/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 702522223
Principal investigator 1 Avanir Pharmaceuticals, Inc. $1,154.10 05/09/2019 Non-covered Recipient Entity
ANI NEUROLOGY PLLC
15-AVP-786-303 No dispute reported 06/30/2026 656017075
Principal investigator 1 Eisai Inc. $956.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522075
Principal investigator 1 Eisai Inc. $605.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522077
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522079
Principal investigator 1 Eisai Inc. $382.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522081
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522083
Principal investigator 1 Eisai Inc. $1,672.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522085
Principal investigator 1 Eisai Inc. $956.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522087
Principal investigator 1 Eisai Inc. $1,859.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522089
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522091
Principal investigator 1 Eisai Inc. $2,005.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522093
Principal investigator 1 Eisai Inc. $2,360.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522095
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522097
Principal investigator 1 Eisai Inc. $2,008.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522099
Principal investigator 1 Eisai Inc. $3,287.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522101
Principal investigator 1 Eisai Inc. $1,875.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522103
Principal investigator 1 Eisai Inc. $2,212.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522105
Principal investigator 1 Eisai Inc. $1,677.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522107
Principal investigator 1 Eisai Inc. $2,731.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522109
Principal investigator 1 Eisai Inc. $1,677.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522111
Principal investigator 1 Eisai Inc. $956.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522113
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522115
Principal investigator 1 Eisai Inc. $1,672.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522117
Principal investigator 1 Eisai Inc. $956.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522119
Principal investigator 1 Eisai Inc. $1,859.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522121
Principal investigator 1 Eisai Inc. $75.00 05/07/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522123
Principal investigator 1 ACADIA Pharmaceuticals Inc $1,500.00 05/01/2019 Non-covered Recipient Entity
ANI NEUROLOGY PLLC
ACP-103-033 No dispute reported 06/30/2026 699989079
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 05/01/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576673
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $40.00 05/01/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576695
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $12.50 05/01/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576697
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $59.94 04/25/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576731
Principal investigator 1 Eisai Inc. $1,706.00 04/23/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702522211
Principal investigator 1 Eisai Inc. $1,234.00 04/23/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702522213
Principal investigator 1 Eisai Inc. $2,500.20 04/17/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 702522221
Principal investigator 1 Genentech, Inc. $16,098.00 04/08/2019 Non-covered Recipient Entity
ANI NEUROLOGY PLLC
SC PROOF OF EFFICACY STUDY No dispute reported 06/30/2026 681085349
Principal investigator 1 Eisai Inc. $1,672.00 04/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522181
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522183
Principal investigator 1 Eisai Inc. $1,186.00 04/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522185
Principal investigator 1 Eisai Inc. $1,875.00 04/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522187
Principal investigator 1 Eisai Inc. $2,212.00 04/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522189
Principal investigator 1 Eisai Inc. $2,360.00 04/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522191
Principal investigator 1 Eisai Inc. $2,008.00 04/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522193
Principal investigator 1 Eisai Inc. $956.00 04/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522195
Principal investigator 1 Eisai Inc. $1,859.00 04/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522197
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522199
Principal investigator 1 Eisai Inc. $605.00 04/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522201
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522203
Principal investigator 1 Eisai Inc. $382.00 04/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522205
Principal investigator 1 Eisai Inc. $75.00 04/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522207
Principal investigator 1 Eisai Inc. $3,956.00 04/02/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522209
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 04/01/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576581
Principal investigator 1 Eli Lilly and Company $25,504.00 03/27/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A STUDY OF HEALTH CARE USE AND COSTS IN PARTICIPANTS WITH EARLY STAGE ALZHEIMER'S DISEASE AD GERAS US No dispute reported 06/30/2026 654287573
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $139.86 03/26/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576175
Principal investigator 1 Eisai Inc. $352.80 03/20/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 702522219
Principal investigator 1 Eisai Inc. $57,247.57 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-controlled, Double-blind, Parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding Study to Evaluate Safety, Tolerability and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521979
Principal investigator 1 Eisai Inc. $1,672.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521981
Principal investigator 1 Eisai Inc. $956.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521983
Principal investigator 1 Eisai Inc. $3,956.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521985
Principal investigator 1 Eisai Inc. $1,186.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521987
Principal investigator 1 Eisai Inc. $1,186.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521989
Principal investigator 1 Eisai Inc. $1,186.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521991
Principal investigator 1 Eisai Inc. $2,731.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521993
Principal investigator 1 Eisai Inc. $1,186.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521995
Principal investigator 1 Eisai Inc. $2,360.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521997
Principal investigator 1 Eisai Inc. $2,008.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521999
Principal investigator 1 Eisai Inc. $3,287.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522001
Principal investigator 1 Eisai Inc. $1,859.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522003
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522005
Principal investigator 1 Eisai Inc. $605.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522007
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522009
Principal investigator 1 Eisai Inc. $382.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522011
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522013
Principal investigator 1 Eisai Inc. $1,672.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522015
Principal investigator 1 Eisai Inc. $75.00 03/12/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702522017
Principal investigator 1 Genentech, Inc. $2,856.00 03/08/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
GANTENERUMAB IN EARLY AD No dispute reported 06/30/2026 681082023
Principal investigator 1 Avanir Pharmaceuticals, Inc. $1,154.10 03/07/2019 Non-covered Recipient Entity
ANI NEUROLOGY PLLC
15-AVP-786-303 No dispute reported 06/30/2026 656017071
Principal investigator 1 Avanir Pharmaceuticals, Inc. $875.00 03/07/2019 Non-covered Recipient Entity
ANI NEUROLOGY PLLC
15-AVP-786-303 No dispute reported 06/30/2026 656017073
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 03/01/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576419
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $167.80 02/25/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576173
Principal investigator 1 Eisai Inc. $639.00 02/13/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 702522217
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 02/01/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576309
Principal investigator 1 Eisai Inc. $4,014.90 02/01/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study With Open-Label Extension Phase of the Efficacy and Safety of Lemborexant in Subjects With Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia No dispute reported 06/30/2026 702522215
Principal investigator 1 Novartis Pharmaceuticals Corporation $264,835.85 01/31/2019 Non-covered Recipient Entity
ANI NEUROLOGY PLLC ALZHEIMERS MEMORY CENTER
A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY OF TWO DOSES OF CNP520 IN PARTICIPANTS AT RISK FOR THE ONSET OF CLINICAL SYMPTOMS OF AD No dispute reported 06/30/2026 640709891
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $327.64 01/28/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576171
Principal investigator 1 Merck Sharp & Dohme Corporation $2,420.00 01/28/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 SCH 900931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease Prodromal AD. No dispute reported 06/30/2026 691311485
Principal investigator 1 Eisai Inc. $1,677.00 01/24/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521977
Principal investigator 1 Merck Sharp & Dohme Corporation $2,500.00 01/24/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Phase III, Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Clinical Trial to Study the Efficacy and Safety of MK-8931 SCH 900931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer s Disease Prodromal AD. No dispute reported 06/30/2026 691303883
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $127,029.73 01/22/2019 Non-covered Recipient Entity
ANI Neurology PLLC
PoCC dose finding in Mild to Moderate AD No dispute reported 06/30/2026 704144787
Principal investigator 1 Genentech, Inc. $12,676.00 01/08/2019 Non-covered Recipient Entity
ANI NEUROLOGY PLLC
SC PROOF OF EFFICACY STUDY No dispute reported 06/30/2026 681082511
Principal investigator 1 Eisai Inc. $1,234.00 01/03/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702521953
Principal investigator 1 Eisai Inc. $1,706.00 01/03/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, Randomized, Proof-of-Concept, Dose-Finding Study To Evaluate Safety, Tolerability, and Efficacy of E2609 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease (Prodromal Alzheimer's Disease) and Mild to Moderate Dementia Due to Alzheimer's Disease No dispute reported 06/30/2026 702521955
Principal investigator 1 Eisai Inc. $75.00 01/03/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521957
Principal investigator 1 Eisai Inc. $605.00 01/03/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521959
Principal investigator 1 Eisai Inc. $75.00 01/03/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521961
Principal investigator 1 Eisai Inc. $1,672.00 01/03/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521963
Principal investigator 1 Eisai Inc. $956.00 01/03/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521965
Principal investigator 1 Eisai Inc. $1,859.00 01/03/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521967
Principal investigator 1 Eisai Inc. $75.00 01/03/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521969
Principal investigator 1 Eisai Inc. $2,731.00 01/03/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521971
Principal investigator 1 Eisai Inc. $2,212.00 01/03/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521973
Principal investigator 1 Eisai Inc. $2,360.00 01/03/2019 Non-covered Recipient Entity
ALZHEIMERS MEMORY CENTER
A Placebo-Controlled, Double-Blind, Parallel-Group, 24-Month Study With an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Subjects With Early Alzheimer's Disease No dispute reported 06/30/2026 702521975
Principal investigator 1 Biogen, Inc. $625,961.05 01/02/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's Disease No dispute reported 06/30/2026 675309467
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $34.30 01/01/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576035
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $40.00 01/01/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576093
Principal investigator 1 Boehringer Ingelheim RCV GmbH & Co KG $12.50 01/01/2019 Non-covered Recipient Entity
Ani Neurology PLLC Alzheimers Memory Center
PoCC/dose-finding in Mild to Moderate AD No dispute reported 06/30/2026 703576095
Principal investigator 1 Novartis Pharmaceuticals Corporation $149,689.88 01/01/2019 Non-covered Recipient Entity
ANI NEUROLOGY PLLC DBA ALZHEIMERS MEMORY CENTER
A 5 YEAR PROSPECTIVE STUDY OF AN ANTI AMYLOID THERAPY CAD106 OR CNP520 IN SLOWING AND OR POSTPONING COGNITIVE DECLINE IN ASYMPTOMATIC APOE 4 HOMOZYGOTES AT RISK FOR DEVELOPING ALZHEIMERS DISEASE DEMENTIA No dispute reported 06/30/2026 640709899